Learning targets: Old social media posts, hashtags, sketchy ingredients, and high-risk claims

Hashtags can make compliant posts very non-compliant

Learning targets: Old social media posts, hashtags, sketchy ingredients, and high-risk claims

#WarningLetterWednesday contains old social media posts, claims made in hashtags, sketchy ingredients, and high-risk claims.


🔷Old social media posts containing claims is a strong enforcement trend, but the ages of the posted cited in recent letters are more aged than the standard 2-3 years. I recently wrote about a 2014 re-tweet being mentioned in a letter here


👉This letter includes Facebook posts from 2016. Wow, the FDA is digging deep into the company's social media, and this is an enforcement trend. Guess what, I made a "helpful hints" video about this. 

➡️ From warning letter.

June 2, 2016 (Facebook) post: “Phenibut is known as a GABA analogue. Outside the US many countries around the world use phenibut clinically for symptoms of PTSD, anxiety, depression and insomnia.”


Hashtags are claims and this is a great example of how a company has taken a relatively lower risk post and made it high risk with a high risk hashtag. Here is a video on this topic. 

➡️ From warning letter. On your February 27, 2017 (Instagram) post: #anxietyrelief” and “MOOD ELEVATION -ENHANCED SLEEP- HEIGHTENED FOCUS”


🔷I am unsurprised this letter contains the high-risk words anxiety and depression. Anxiety products claims enforcement was up 95% in 2021, and 75% of those warning letters had both anxiety and depression, a one-two compliance punch. It is important to remember this includes all online marketing, and these are pieced together for one picture of noncompliance. Here is a video and post about anxiety claims enforcement. 

👉Insomnia claims are also mentioned in the letter which I have also written about here. These darn companies need to read Warning Letter Wednesday.😁 


🔷There are some surprisingly low-risk structure-function claims cited in this warning letter. In my opinion, these are "secondary addition" claims that are not likely to attract a warning letter on their own. It is, however, interesting to see what the FDA considers a claim worthy of a warning letter "call out."

➡️ From warning letter.

..Product packaging: • “Stress Reducing • Mood Boosting”


Also worth mentioning is the use of phenibut, which the FDA does not consider a dietary ingredient.


🔷Read the warning letter here.


👉Check out my WLW LinkedIn Group

Get Warning Letter Wednesday in your Inbox